"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...

The Pill Hill homes between Third Street and Ninth Street Southwest and Seventh and 10th Avenue Southwest were built from ...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...

Choose from Fda Drug stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection Essentials collection ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today ...

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...

A modified herpes virus that targets spinal cord nerve cells to treat neurogenic bladder in people with spinal cord injury is underway in a first-in-human clinical trial by UTHealth Houston at TIRR ...

The company behind the deadly 2022 infant formula outbreak and recall situation was represented by the man expected to be appointed to lead the FDA division that oversees food safety. Kyle ...